Fenofibrate Attenuated Glucose-Induced Mesangial Cells Proliferation and Extracellular Matrix Synthesis via PI3K/AKT and ERK1/2

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Zeng, Rui ^a   Xiong, Yan ^a,b   Zhu, Fengming ^a   Ma, Zufu ^a   Liao, Wenhui ^a   He, Yong ^a,c   He, JinSeng ^a   Li, Wei ^a   Yang, Juan ^a   Lu, Qian ^a   Xu, Gang ^a   Yao, Ying ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b Wuhan No 1 Hospital   (China)

^c Wuhan No 4 Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 4; FENOFIBRATE; METHYLTHIAZOLETETRAZOLIUM; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TETRAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; EXTRACELLULAR MATRIX; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; GENE REPRESSION; MESANGIUM CELL; NONHUMAN; RAT; RENAL PROTECTION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING;

ANIMALS; CELL CYCLE CHECKPOINTS; CELL LINE; CELL PROLIFERATION; COLLAGEN TYPE IV; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; EXTRACELLULAR MATRIX; FENOFIBRATE; GLUCOSE; MAP KINASE SIGNALING SYSTEM; MESANGIAL CELLS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PPAR ALPHA; PROTO-ONCOGENE PROTEINS C-AKT; RATS; UP-REGULATION;

EID: 84885147284     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0076836     Document Type: Article

References (25)

1. Lee S, Sharma K, (2004) The pathogenesis of fibrosis and renal disease in scleroderma: recent insights from glomerulosclerosis. Curr Rheumatol Rep 6(2):: 141-148. doi:10.1007/s11926-004-0059-3. PubMed: 15016345.
2. Issemann I, Green S, (1990) Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347: 645-650. doi:10.1038/347645a0. PubMed: 2129546.
3. Hiukka A, Maranghi M, Matikainen N, Taskinen MR, (2010) PPARα: an emerging therapeutic target in diabetic microvascular damage. Nat. Rev Endocrinal (6): pp. 454-463.
4. Keating GM, (2011) Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus. Am J Cardiovasc Drugs 11(4):: 227-247. doi:10.2165/11207690-000000000-00000. PubMed: 21675801.
5. Portilla D, Dai G, Peters JM, Gonzalez FJ, Crew MD, et al. (2000) Etomoxir-induced PPARα-modulated enzymes protect during acute renal failure. Am J Physiol 278(4):: 667-675.
6. Kono K, Kamijo Y, Hora K, Takahashi K, Higuchi M, et al. (2009) PPARalpha attenuates the proinflammatory response in activated mesangial cells. Am J Physiol Renal Physiol 296: F328-F336. PubMed: 19036849.
7. Ansquer JC, Foucher C, Rattier S, Taskinen MR, Steiner G, et al. (2005) Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: Results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis 45(3):: 485-493. doi:10.1053/j.ajkd.2004.11.004. PubMed: 15754270.
8. Kono K, Kamijo Y, Hora K, Takahashi K, Higuchi M, et al. (2009) PPARalpha attenuates the proinflammatory response in activated mesangial cells. Am J Physiol Renal Physiol 296: F328-F336. PubMed: 19036849.
9. Park CW, Kim HW, Ko SH, Chung HW, Lim SW, et al. (2006) Accelerated diabetic nephropathy in mice lacking the peroxisome proliferator-activated receptor alpha. Diabetes 55(4):: 885-893. doi:10.2337/diabetes.55.04.06.db05-1329. PubMed: 16567507.
10. Marks JB, Raskin P, (1998) Nephropathy and hypertension in diabetes. Med Clin North Am 2: 877-907. PubMed: 9706125.
11. Lee JJ, Yu JY, Zhang WY, Kim TJ, Lim Y, et al. (2011) Inhibitory effect of fenofibrate on neointima hyperplasia via G(0)/G(1) arrest of cell proliferation. Eur J Pharmacol 650(1):: 342-349. doi:10.1016/j.ejphar.2010.10.046. PubMed: 21040719.
12. Ingrom A, Ly H, Thai K, Kang MJ, Scholey JW, (1999) Mesangial cell signaling cascade in response to mechanical strain and glucose. Kidney Int 56: 1721-1731. doi:10.1046/j.1523-1755.1999.00743.x. PubMed: 10571780.
13. Hirasawa Y, Sakai T, Ito M, Yoshimura H, Feng Y, et al. (2011) Advanced glycation end product cholesterol aggregated protein accelerates the proliferation of mesangial cells mediated by transforming-growth-factor-beta 1 receptors and the ERK-MAPK pathway. Eur J Pharmacol 672(1-3):: 159-168. doi:10.1016/j.ejphar.2011.09.185.
14. Ohashi N, Urushihara M, Satou R, Kobori H, (2010) Glomerular angiotensinogen is induced in mesangial cells in diabetic rats via reactive oxygen species--ERK/JNK pathways. Hypertens Res 33(11):: 1174-1181. doi:10.1038/hr.2010.143. PubMed: 20686488.
15. Heo JS, Han HJ, (2006) High glucose increase cell cycle regulatory proteins level of mouse embryonic stem cells via PI3-K/Akt and MAPKs signal pathways. J Cell Physiol 209(1):: 94-102. doi:10.1002/jcp.20706. PubMed: 16775839.
16. Goetze S, Eilers F, Bungenstock A, Kintscher U, Stawowy P, et al. (2002) PPAR activators inhibit endothelial cell migration by targeting Akt. Biochem Biophys Res Commun 239: 1431-1437. PubMed: 12054675.
17. Grabacka M, Plonka PM, Urbanska K, Reiss K, (2006) Peroxisome proliferator-activated receptor alpha activation decreases metastatic potential of melanoma cells in vitro via down-regulation of Akt. Clin Cancer Res 12(10):: 3028-3036. doi:10.1158/1078-0432.CCR-05-2556. PubMed: 16707598.
18. Park CW, Zhang Y, Zhang X, Wu J, Chen L, et al. (2006) PPARalpha agonist fenofibrate improves diabetic nephropathy in db/db mice. Kidney Int 69(9):: 1511-1517. doi:10.1038/sj.ki.5000209. PubMed: 16672921.
19. Cosio FG, (1995) Effects of high glucose concentrations on human mesangial cell proliferation. J Am Soc Nephrol 5: 1600-1609. PubMed: 7756594.
20. Lee S, Lee S, Sharma K, (2004) The pathogenesis of fibrosis and renal disease in scleroderma: recent insights from glomerulosclerosis. Curr Rheumatol Rep 6(2):: 141-148. doi:10.1007/s11926-004-0059-3. PubMed: 15016345.
21. Mason RM, Wahab NA, (2003) Extracellular matrix metabolism in diabetic nephropathy. J Am Soc Nephrol 14: 1358-1373. doi:10.1097/01.ASN.0000065640.77499.D7. PubMed: 12707406.
22. Shiojima I, Walsh K, (2002) Role of Akt signaling in vascular homeostasis and angiogenesis. Circ Res 90: 1243-1250. doi:10.1161/01.RES.0000022200.71892.9F. PubMed: 12089061.
23. Mebratu Y, Tesfaigzi Y, (2009) How ERK1/2 activation controls cell proliferation and cell death: Is subcellular localization the answer? Cell Cycle 8(8):: 1168-1175. doi:10.4161/cc.8.8.8147. PubMed: 19282669.
24. Heljić M, Brazil DP, (2011) Protein kinase B/Akt regulation in diabetic kidney disease. Front Biosci (Schol Ed) Volumes 3: 98-104. doi:10.2741/s135.
25. Yoo KD, Park ES, Lim Y, Kang SI, Yoo SH, et al. (2012) Clitocybin A, a novel isoindolinone, from the mushroom Clitocybe aurantiaca, inhibits cell proliferation through G1 phase arrest by regulating the PI3K/Akt cascade in vascular smooth muscle cells. J Pharmacol Sci 118(2):: 171-177. doi:10.1254/jphs.11159FP. PubMed: 22343364.